Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 83.9%

Neg 0% Neu 83.9% Pos 0%

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.

Comments

No comments yet. Be the first!